Albion Venture Capital Trust PLC: Half-yearly Financial Report
Albion Venture Capital Trust
PLC
LEI Code: 213800JKELS32V2OK421
As required by the UK Listing Authority's
Disclosure Guidance and Transparency Rule 4.2, Albion Venture
Capital Trust PLC today makes public its information relating to
the Half-yearly Financial Report (which is unaudited) for the six
months to 30 September 2023. This announcement was approved by the
Board of Directors on 14 December 2023.
The full Half-yearly Financial Report (which is
unaudited) for the period to 30 September 2023 will shortly be sent
to shareholders and will be available on the Albion Capital Group
LLP website by
clicking www.albion.capital/funds/AAVC/30Sep2023.pdf.
Investment objective and
policy
The Company is a Venture Capital Trust and the
investment policy is intended to produce a regular and predictable
dividend stream with an appreciation in capital value.
Investment policy The Company
will invest in a broad portfolio of smaller, unquoted growth
businesses across a variety of sectors including higher risk
technology companies. Investments may take the form of equity or a
mixture of equity and loans.
Allocation of funds will be determined by the
investment opportunities which become available but efforts will be
made to ensure that the portfolio is diversified both in terms of
sector and stage of maturity of company. Funds held pending
investment or for liquidity purposes will be held as cash on
deposit.
Risk diversification and maximum
exposures Risk is spread by investing in a number of
different businesses within venture capital trust qualifying
industry sectors. The maximum amount which the Company will invest
in a single portfolio company is 15% of the Company's assets at
cost, thus ensuring a spread of investment risk. The value of an
individual investment may increase over time as a result of trading
progress and it is possible that it may grow in value to a point
where it represents a significantly higher proportion of total
assets prior to a realisation opportunity being available.
Gearing The Company's maximum
exposure in relation to gearing is restricted to 10% of the
adjusted share capital and reserves.
Financial calendar
5 January
2024 31 January 2024 31 March |
Record date
for second dividend Payment date of second dividend Financial year
end |
Financial summary
|
Unaudited six months ended 30 September 2023 (pence per
share) |
Unaudited six months ended 30 September 2022 (pence per share) |
Audited year ended 31 March 2023 (pence per share) |
Opening net asset value |
50.88 |
53.38 |
53.38 |
Capital
(loss)/return |
(2.41) |
0.60 |
(0.34) |
Revenue
return |
0.26 |
|
0.24 |
|
0.44 |
|
Total
(loss)/return |
(2.15) |
0.84 |
0.10 |
Dividends
paid |
(1.27) |
(1.33) |
(2.65) |
Impact from share capital movements |
0.01 |
0.01 |
0.05 |
Net asset value |
47.47 |
52.90 |
50.88 |
Total shareholder value |
Ordinary shares (pence per
share) |
Net asset value as at 30 September 2023 |
47.47 |
Total dividends paid to 30 September 2023 |
193.26 |
Total shareholder value to 30 September 2023 |
240.73 |
A more detailed breakdown of the dividends paid
per year can be found at www.albion.capital/funds/AAVC under the
‘Dividend History’ section.
The financial summary above is for the Company,
Albion Venture Capital Trust PLC Ordinary shares only. Details of
the financial performance of the C shares and Albion Prime VCT PLC,
which have been merged into the Company, can be found on the
Company’s webpage at www.albion.capital/funds/AAVC under the
‘Financial summary for previous funds’ section.
The Directors have declared a second
dividend of 1.19 pence per share for the year ending 31 March 2024,
which will be paid on 31 January 2024 to shareholders on the
register on 5 January 2024.
Interim management report
Introduction In the six months
to 30 September 2023, the Company generated a total loss of 2.15
pence per share, representing a 4.2% decrease on the opening net
asset value (“NAV”). Despite the disappointing loss for the period,
which reflects the challenging macroeconomic and geopolitical
backdrop, the Board is encouraged by the resilience and revenue
growth from a number of our portfolio companies.
Results and dividends The total
loss for the six months to 30 September 2023 was £3.0 million (30
September 2022: gain of £1.0 million; year ended 31 March 2023:
gain of £0.1 million). The Company paid a first dividend of 1.27
pence per share during the period to 30 September 2023 (30
September 2022: 1.33 pence per share). As a result, the NAV has
decreased to 47.47 pence per share on 30 September 2023 (31 March
2023: 50.88 pence per share).
In line with our variable dividend policy
targeting a dividend around 5% of NAV per annum, the Company will
pay a second dividend for the financial year ending 31 March 2024
of 1.19 pence per share on 31 January 2024 to shareholders on the
register on 5 January 2024, being 2.5% of the 30 September 2023
NAV.
This will bring the total dividends paid for the
year ending 31 March 2024 to 2.46 pence per share, which equates to
a 4.8% yield on the opening NAV of 50.88 pence per share.
Investment performance and
progress The loss on our portfolio of investments for the
six months to 30 September 2023 was £2.9 million (30 September
2022: gain of £1.2 million; year ended 31 March 2023: gain of £0.6
million). The key upward movements in the period include: Ophelos,
an investment that was held for only one year, which was sold after
the period end for 2 times cost, with an uplift of £0.4 million
recognised during the period; and Accelex, a £0.3 million valuation
uplift, after an externally led Series A funding round. Loan stock
interest and dividend income, predominantly from the renewable
energy investments, accounted for £0.5 million of the £0.8 million
of income generated by the Company during the period.
The challenging economic environment has
resulted in falling valuations in some technology and healthcare
companies which has consequently led to some write-downs in our
portfolio. The largest of these have been: Threadneedle Software
Holdings (T/A Solidatus) (loss of £0.6 million); Healios (loss of
£0.5 million); Brytlyt (loss of £0.5 million); and The Evewell
Group (loss of £0.5 million).
The Company’s renewable energy generation
investments have seen an aggregate valuation reduction of £0.6
million. This reduction reflects the impact of higher interest
rates, and the expectation of falling electricity prices and
inflation, in addition to a reduction in the remaining life of the
assets.
Our top 3 portfolio companies now account for
14.7% of the Company’s NAV (30 September 2022: 16.2%; 31 March
2023: 14.4%).
Given the economic uncertainty of high inflation
and rising interest rates, the period to 30 September 2023 has been
more subdued in terms of new investment activity. During the
period, the Company has invested £0.5 million into two new
portfolio companies (Phasecraft and Kennek Solutions) and £1.4
million into existing portfolio companies to help support them as
they continue to grow, including £0.7 million into Gravitee Topco
(T/A Gravitee.io) and £0.6 million into uMedeor (T/A uMed).
Investment activity has seen a recovery after
the period end, with £1.8 million invested into new and follow on
investments since 30 September 2023.
Further details of the portfolio of investments
and investment realisations can be found below.
Investment portfolio by sector
The pie chart at the end of this announcement shows the different
sectors in which the Company’s assets, at carrying value, were
invested at 30 September 2023.
Change of Auditor As announced
on 30 October 2023, following a formal and rigorous audit tender
process, the Company was pleased to announce the appointment of
Johnston Carmichael LLP (“Johnston Carmichael”) as the Company’s
Auditor with immediate effect. Johnston Carmichael will conduct the
audit of the Annual Report and Financial Statements for the year
ended 31 March 2024.
The Company and the Manager would like to
express their appreciation and gratitude to BDO for their diligent
service over the last 16 years.
Share buy-backs It remains the
Board’s primary objective to maintain sufficient resources for
investment in new and existing portfolio companies and for the
continued payment of dividends to shareholders. The Board’s policy
is to buy-back shares in the market, subject to the overall
constraint that such purchases are in the Company’s
interest. It is the Board’s intention for such buy-backs to be
in the region of a 5% discount to net asset value, so far as market
conditions and liquidity permit. The Board continues to review the
use of buy-backs and is satisfied that it is an important means of
providing market liquidity for shareholders.
Risks and uncertainties The
Company faces a number of significant risks including high interest
rates, high levels of inflation, the ongoing impact of geopolitical
tensions, and an expected period of low economic growth in the UK.
The Company’s focus on technology investments may result in greater
valuation volatility in the current economic climate. Overall
investment risk is mitigated in a number of ways. In particular,
the Manager is continually assessing the exposure to these risks
for each portfolio company and mitigating actions, where possible,
are being implemented.
In accordance with the Disclosure Guidance and
Trasnparency Rules (“DTR”) 4.2.7, the Board confirms that the
principal risks and uncertainties facing the Company have not
materially changed from those identified in the Annual Report and
Financial Statements for the year ended 31 March 2023. The Board
considers that the present processes for mitigating those risks
remain appropriate.
The principal risks faced by the Company
are:
- Investment, performance, technology and valuation risk;
- VCT approval and regulatory change risk;
- Regulatory and compliance risk;
- Operational and internal control risk;
- Cyber and data security risk;
- Economic and political risk;
- Environmental, social and governance (“ESG”) risk; and
- Liquidity risk.
A detailed explanation of the principal risks
facing the Company can be found in the Annual Report and Financial
Statements for the year ended 31 March 2023 on pages 23 to 25,
copies of which are available on the Company’s webpage on the
Manager’s website at www.albion.capital/funds/AAVC under the
‘Financial Reports and Circulars’ section.
Transactions with the Manager
Details of the transactions that took place with the Manager during
the period can be found in note 5. Details of related party
transactions can be found in note 11.
Move to electronic communications
The Board wishes to minimise the environmental impact of how the
Company communicates with its shareholders. With this in mind,
those shareholders that continue to receive physical copies of the
Annual Report and other documentation, will receive a letter
alongside this Half-yearly Financial Report explaining the
forthcoming move to electronic communications.
Outlook and prospects The
Company still faces many uncertainties, with high levels of
inflation, elevated interest rates and geopolitical tensions, but
the portfolio remains relatively resilient during these challenging
times. The portfolio is well diversified, with companies at
different stages of maturity and targeted at sectors such as
healthcare, data analytics and FinTech. Whilst we are disappointed
with the loss for the period, we believe these sectors of focus can
provide opportunities for growth, and to yield positive results for
the Company and its shareholders over the longer-term.
Richard Glover Chairman 14
December 2023
Portfolio of investments
Fixed asset investments |
% voting rights |
As at 30 September 2023 |
|
Change in value for the
period**£'000 |
Cost* £’000 |
Cumulative movement in value £’000 |
Value £’000 |
|
Chonais River Hydro |
9.2 |
3,074 |
1,148 |
4,222 |
|
(306) |
Radnor House School (TopCo) |
6.9 |
1,259 |
1,607 |
2,866 |
|
58 |
Cantab Research (T/A Speechmatics) |
2.6 |
2,234 |
392 |
2,626 |
|
- |
Gravitee TopCo (T/A Gravitee.io) |
3.9 |
2,189 |
390 |
2,579 |
|
- |
Seldon Technologies |
7.4 |
2,539 |
- |
2,539 |
|
(323) |
The Evewell Group |
5.2 |
1,272 |
992 |
2,264 |
|
(492) |
Runa Network |
2.0 |
1,429 |
520 |
1,949 |
|
94 |
Elliptic Enterprises |
1.4 |
1,913 |
- |
1,913 |
|
- |
Gharagain River Hydro |
11.5 |
1,363 |
512 |
1,875 |
|
(138) |
Threadneedle Software Holdings (T/A Solidatus) |
2.1 |
1,262 |
145 |
1,407 |
|
(607) |
Healios |
2.4 |
1,517 |
(208) |
1,309 |
|
(547) |
TransFICC |
2.1 |
1,025 |
271 |
1,296 |
|
- |
uMedeor (T/A uMed) |
4.1 |
1,061 |
167 |
1,228 |
|
- |
Peppy Health |
1.3 |
1,207 |
- |
1,207 |
|
- |
The Street by Street Solar Programme |
6.5 |
676 |
472 |
1,148 |
|
(56) |
Kew Green VCT (Stansted) |
45.2 |
1,234 |
(91) |
1,143 |
|
27 |
MHS 1 |
14.8 |
1,026 |
72 |
1,098 |
|
12 |
Accelex Technology |
3.6 |
788 |
305 |
1,093 |
|
305 |
Beddlestead |
9.1 |
1,142 |
(65) |
1,077 |
|
49 |
NuvoAir Holdings |
2.3 |
943 |
124 |
1,067 |
|
(301) |
Ophelos |
1.7 |
433 |
423 |
856 |
|
422 |
Toqio FinTech Holdings |
1.2 |
838 |
- |
838 |
|
- |
Alto Prodotto Wind |
7.4 |
436 |
289 |
725 |
|
(57) |
Regenerco Renewable Energy |
4.5 |
451 |
223 |
674 |
|
(6) |
Erin Solar |
18.6 |
520 |
21 |
541 |
|
6 |
GX Molecular (T/A CS Genetics) |
1.7 |
496 |
- |
496 |
|
- |
PerchPeek |
1.9 |
567 |
(140) |
427 |
|
(141) |
OutThink |
1.6 |
410 |
- |
410 |
|
- |
Dragon Hydro |
7.3 |
234 |
171 |
405 |
|
(14) |
PeakData |
1.3 |
564 |
(216) |
348 |
|
(253) |
Diffblue |
1.5 |
343 |
- |
343 |
|
- |
Harvest AD |
0.0 |
307 |
36 |
343 |
|
3 |
Phasecraft |
0.6 |
321 |
- |
321 |
|
- |
AVESI |
7.4 |
242 |
51 |
293 |
|
(3) |
PetsApp |
1.6 |
286 |
- |
286 |
|
- |
Imandra |
1.3 |
175 |
90 |
265 |
|
3 |
5Mins AI |
1.3 |
229 |
- |
229 |
|
- |
Ramp Software |
1.5 |
227 |
- |
227 |
|
- |
Regulatory Genome Development |
1.0 |
161 |
55 |
216 |
|
55 |
Brytlyt |
3.4 |
727 |
(512) |
215 |
|
(511) |
Premier Leisure (Suffolk) |
9.9 |
175 |
37 |
212 |
|
3 |
Arecor Therapeutics PLC |
0.3 |
90 |
74 |
164 |
|
(20) |
Tem Energy |
1.2 |
154 |
- |
154 |
|
- |
Greenenerco |
3.9 |
90 |
63 |
153 |
|
(11) |
Kennek Solutions |
0.4 |
131 |
- |
131 |
|
- |
Neurofenix |
11.7 |
351 |
(247) |
104 |
|
(142) |
Symetrica |
0.3 |
95 |
(6) |
89 |
|
(1) |
InFact Systems (T/A InFact) |
1.5 |
80 |
- |
80 |
|
- |
Limitless Technology |
1.8 |
471 |
(471) |
- |
|
(113) |
Total fixed asset investments |
|
38,757 |
6,694 |
45,451 |
|
(3,005) |
*The cost includes the original cost from Albion
Venture Capital Trust PLC and the carried over value on merger from
Albion Prime VCT PLC as at 25 September 2012. ** As adjusted for
additions and disposals during the period.
Fixed asset investment
realisations during the period to 30
September 2023 |
Cost* £’000 |
Opening carrying value £’000 |
Disposal proceeds £’000 |
Total realised gain/(loss)
£’000 |
Gain/(loss) on opening value
£’000 |
Disposals: |
|
|
|
|
|
Arecor Therapeutics PLC |
40 |
83 |
66 |
26 |
(17) |
uMotif |
1,078 |
70 |
1 |
(1,077) |
(69) |
|
|
|
|
|
|
Loan stock repayments, conversions and other: |
|
|
|
|
|
uMedeor (T/A uMed) |
167 |
174 |
176 |
9 |
2 |
Alto Prodotto Wind |
25 |
33 |
33 |
8 |
- |
Dragon Hydro |
15 |
15 |
15 |
- |
- |
Greenenerco |
5 |
6 |
6 |
1 |
- |
Total realisations |
1,330 |
381 |
297 |
(1,033) |
(84) |
*The cost includes the original cost from Albion
Venture Capital Trust PLC and the carried over value on merger from
Albion Prime VCT PLC as at 25 September 2012.
Total change in value of investments for the
period |
|
|
(3,005) |
Movement in loan stock accrued interest |
|
|
|
|
|
36 |
Unrealised losses sub-total |
|
|
|
|
|
(2,969) |
Realised losses in current period |
|
|
|
|
|
(84) |
Unwinding of discount on deferred consideration |
|
|
|
|
|
147 |
Total losses on investments as per Income
statement |
|
|
(2,906) |
Responsibility statement
The Directors, Richard Glover, Ann Berresford,
Neeta Patel and Richard Wilson, are responsible for preparing the
Half-yearly Financial Report. In preparing these condensed
Financial Statements for the period to 30 September 2023 we, the
Directors of the Company, confirm that to the best of our
knowledge:
(a) the condensed set of Financial Statements,
which has been prepared in accordance with Financial Reporting
Standard 104 “Interim Financial Reporting”, give a true and fair
view of the assets, liabilities, financial position and profit and
loss of the Company as required by DTR 4.2.4R;
(b) the Interim management report includes a
fair review of the information required by DTR 4.2.7R (indication
of important events during the first six months and description of
principal risks and uncertainties for the remaining six months of
the year); and
(c) the Interim management report includes a
fair review of the information required by DTR 4.2.8R (disclosure
of related parties’ transactions and changes therein).
This Half-yearly Financial Report has not been
audited or reviewed by the Auditor.
For and on behalf of the Board
Richard Glover Chairman 14
December 2023
Condensed income statement
|
|
Unaudited six months ended
30 September 2023 |
Unaudited six months ended 30 September 2022 |
Audited year ended 31 March 2023 |
|
Note |
Revenue £’000 |
Capital £’000 |
Total £’000 |
Revenue £’000 |
Capital £’000 |
Total £’000 |
Revenue £’000 |
Capital £’000 |
Total £’000 |
Net (losses)/gains on investments |
3 |
- |
(2,906) |
(2,906) |
- |
1,207 |
1,207 |
- |
577 |
577 |
Investment income |
4 |
769 |
- |
769 |
607 |
- |
607 |
1,202 |
- |
1,202 |
Investment Manager’s fees |
5 |
(63) |
(564) |
(627) |
(59) |
(528) |
(587) |
(122) |
(1,097) |
(1,219) |
Other expenses |
|
(240) |
- |
(240) |
(217) |
- |
(217) |
(435) |
- |
(435) |
Profit/(loss) on ordinary activities before
tax |
|
466 |
(3,470) |
(3,004) |
331 |
679 |
1,010 |
645 |
(520) |
125 |
Tax (charge)/credit on ordinary activities |
|
(98) |
98 |
- |
(46) |
46 |
- |
(99) |
99 |
- |
Profit/(loss) and total comprehensive income attributable
to shareholders |
|
368 |
(3,372) |
(3,004) |
285 |
725 |
1,010 |
546 |
(421) |
125 |
Basic and diluted return/(loss) per share
(pence)* |
7 |
0.26 |
(2.41) |
(2.15) |
0.24 |
0.60 |
0.84 |
0.44 |
(0.34) |
0.10 |
*adjusted for treasury shares
The accompanying notes below form an integral
part of this Half-yearly Financial Report.
Comparative figures have been extracted from the
unaudited Half-yearly Financial Report for the six months ended 30
September 2022 and the audited statutory accounts for the year
ended 31 March 2023.
The total column of this Condensed income
statement represents the profit and loss account of the Company.
The supplementary revenue and capital columns have been prepared in
accordance with The Association of Investment Companies’ Statement
of Recommended Practice.
Condensed balance sheet
|
Note |
Unaudited 30 September 2023
£’000 |
Unaudited 30 September 2022 £’000 |
Audited 31 March 2023 £’000 |
Fixed asset investments |
|
45,451 |
44,015 |
46,823 |
|
|
|
|
|
Current assets |
|
|
|
|
Trade and other receivables |
|
2,640 |
2,219 |
1,960 |
Cash in bank and at hand |
|
18,791 |
17,901 |
22,886 |
|
|
21,431 |
20,120 |
24,846 |
|
|
|
|
|
Payables: amounts falling due within one year |
|
|
|
|
Trade and other payables |
|
(676) |
(508) |
(654) |
|
|
|
|
|
Net current assets |
|
20,755 |
19,612 |
24,192 |
|
|
|
|
|
Total assets less current liabilities |
|
66,206 |
63,627 |
71,015 |
|
|
|
|
|
Equity attributable to equity holders |
|
|
|
|
Called-up share capital |
8 |
1,601 |
1,381 |
1,587 |
Share premium |
|
22,193 |
11,121 |
21,531 |
Capital redemption reserve |
|
31 |
31 |
31 |
Unrealised capital reserve |
|
6,395 |
8,163 |
8,415 |
Realised capital reserve |
|
737 |
6,805 |
2,089 |
Other distributable reserve |
|
35,249 |
36,126 |
37,362 |
Total equity shareholders’ funds |
|
66,206 |
63,627 |
71,015 |
Basic and diluted net asset value per share
(pence)* |
|
47.47 |
52.90 |
50.88 |
*excluding treasury shares
The accompanying notes below form an integral
part of this Half-yearly Financial Report.
Comparative figures have been extracted from the
unaudited Half-yearly Financial Report for the six months ended 30
September 2022 and the audited statutory accounts for the year
ended 31 March 2023.
These Financial Statements were approved by the
Board of Directors and authorised for issue on 14 December 2023,
and were signed on its behalf by
Richard Glover Chairman Company
number: 03142609
Condensed statement of changes in
equity
|
Called-up share capital |
Share premium |
Capital redemption reserve |
Unrealised capital reserve |
Realised capital reserve* |
Other distributable reserve* |
Total |
|
£’000 |
£’000 |
£’000 |
£’000 |
£’000 |
£’000 |
£’000 |
At 1 April 2023 |
1,587 |
21,531 |
31 |
8,415 |
2,089 |
37,362 |
71,015 |
(Loss)/return and total comprehensive income for the period |
- |
- |
- |
(2,969) |
(403) |
368 |
(3,004) |
Transfer of previously unrealised losses on realisations of
investments |
- |
- |
- |
949 |
(949) |
- |
- |
Purchase of shares for treasury |
- |
- |
- |
- |
- |
(698) |
(698) |
Issue of equity |
14 |
672 |
- |
- |
- |
- |
686 |
Cost of issue of equity |
- |
(10) |
- |
- |
- |
- |
(10) |
Net dividends paid (note 6) |
- |
- |
- |
- |
- |
(1,783) |
(1,783) |
At 30 September 2023 |
1,601 |
22,193 |
31 |
6,395 |
737 |
35,249 |
66,206 |
At 1 April 2022 |
1,369 |
10,047 |
22 |
6,550 |
7,693 |
38,256 |
63,937 |
Return/(loss) and total comprehensive income for the period |
- |
- |
- |
980 |
(255) |
285 |
1,010 |
Transfer of previously unrealised losses on realisations of
investments |
- |
- |
- |
633 |
(633) |
- |
- |
Purchase of shares for cancellation |
(9) |
- |
9 |
- |
- |
(455) |
(455) |
Purchase of shares for treasury |
- |
- |
- |
- |
- |
(346) |
(346) |
Issue of equity |
21 |
1,094 |
- |
- |
- |
- |
1,115 |
Cost of issue of equity |
- |
(20) |
- |
- |
- |
- |
(20) |
Net dividends paid (note 6) |
- |
- |
- |
- |
- |
(1,614) |
(1,614) |
At 30 September 2022 |
1,381 |
11,121 |
31 |
8,163 |
6,805 |
36,126 |
63,627 |
At 1 April 2022 |
1,369 |
10,047 |
22 |
6,550 |
7,693 |
38,256 |
63,937 |
Return/(loss) and total comprehensive income for the year |
- |
- |
- |
492 |
(913) |
546 |
125 |
Transfer of previously unrealised losses on realisations of
investments |
- |
- |
- |
1,373 |
(1,373) |
- |
- |
Purchase of shares for cancellation |
(9) |
- |
9 |
- |
- |
(455) |
(455) |
Purchase of treasury shares |
- |
- |
- |
- |
- |
(985) |
(985) |
Issue of equity |
227 |
11,754 |
- |
- |
- |
- |
11,981 |
Cost of issue of equity |
- |
(270) |
- |
- |
- |
- |
(270) |
Net dividends paid (note 6) |
- |
- |
- |
- |
(3,318) |
- |
(3,318) |
At 31 March 2023 |
1,587 |
21,531 |
31 |
8,415 |
2,089 |
37,362 |
71,015 |
*Included within these reserves is an amount of
£29,965,000 (30 September 2022: £23,008,000; 31 March 2023:
£20,254,000) which is considered distributable. Over the next two
years an additional £3,583,000 will become distributable. This is
due to the HMRC requirement that the Company cannot use capital
raised in the past three years to make a payment or distribution to
shareholders.
The accompanying notes below form an integral
part of this Half-yearly Financial Report.
Comparative figures have been extracted from the
unaudited Half-yearly Financial Report for the six months ended 30
September 2022 and the audited statutory accounts for the year
ended 31 March 2023.
Condensed statement of cash
flows
|
Unaudited six months ended 30 September
2023 £’000 |
Unaudited six months ended 30 September 2022 £’000 |
Audited year ended 31 March 2023 £’000 |
Cash flow from operating activities |
|
|
|
Loan stock income received |
477 |
411 |
851 |
Dividend income received |
74 |
91 |
121 |
Income from fixed term funds received |
96 |
22 |
85 |
Deposit interest received |
159 |
12 |
55 |
Investment management fee paid |
(658) |
(431) |
(1,019) |
Other cash payments |
(277) |
(253) |
(431) |
UK Corporation tax refund/(paid) |
- |
- |
- |
Net cash flow generated from operating
activities |
(129) |
(148) |
(338) |
|
|
|
|
Cash flow from investing activities |
|
|
|
Purchase of fixed asset investments |
(2,480) |
(5,849) |
(9,425) |
Disposal of fixed asset investments |
236 |
423 |
834 |
Net cash flow generated from investing
activities |
(2,244) |
(5,426) |
(8,591) |
|
|
|
|
Cash flow from financing activities |
|
|
|
Issue of share capital |
405 |
822 |
11,159 |
Cost of issue of equity |
(2) |
(2) |
(6) |
Dividends paid* |
(1,511) |
(1,336) |
(2,758) |
Purchase of own shares (including costs) |
(614) |
(677) |
(1,248) |
Net cash flow generated from financing
activities |
(1,722) |
(1,193) |
7,147 |
|
|
|
|
Decrease in cash in bank and at hand |
(4,095) |
(6,767) |
(1,782) |
Cash in bank and at hand at start of period |
22,886 |
24,668 |
24,668 |
Cash in bank and at hand at end of period |
18,791 |
17,901 |
22,886 |
*The equity dividends paid in the cash flow is
different to the dividends disclosed in note 6 due to the non-cash
effect of the Dividend Reinvestment Scheme.
The accompanying notes below form an integral
part of this Half-yearly Financial Report.
Comparative figures have been extracted from the
unaudited Half-yearly Financial Report for the six months ended 30
September 2022 and the audited statutory accounts for the year
ended 31 March 2023.
Notes to the condensed Financial
Statements
1. Basis of preparation The
condensed Financial Statements have been prepared in accordance
with applicable United Kingdom law and accounting standards,
including Financial Reporting Standard 102 (“FRS 102”), Financial
Reporting Standard 104 – Interim Financial Reporting (“FRS 104”),
and with the Statement of Recommended Practice “Financial
Statements of Investment Trust Companies and Venture Capital
Trusts” (“SORP”) issued by The Association of Investment Companies
(“AIC”). The Financial Statements have been prepared on a going
concern basis.
The preparation of the Financial Statements
requires management to make judgements and estimates that affect
the application of policies and reported amounts of assets,
liabilities, income and expenses. The most critical estimates and
judgements relate to the determination of carrying value of
investments at fair value through profit and loss (“FVTPL”). The
Company values investments by following the International Private
Equity and Venture Capital Valuation (“IPEV”) Guidelines as updated
in 2022 and further detail on the valuation techniques used are
outlined below.
Company information can be found on page 4 of
the Half-yearly Financial Report.
2. Accounting policies
Fixed asset investments The Company’s business is
investing in financial assets with a view to profiting from their
total return in the form of income and capital growth. This
portfolio of financial assets is managed and its performance
evaluated on a fair value basis, in accordance with a documented
investment policy, and information about the portfolio is provided
internally on that basis to the Board.
In accordance with the requirements of FRS 102,
those undertakings in which the Company holds more than 20% of the
equity as part of an investment portfolio are not accounted for
using the equity method. In these circumstances the investment is
measured at FVTPL.
Upon initial recognition (using trade date
accounting) investments, including loan stock, are classified by
the Company as FVTPL and are included at their initial fair value,
which is cost (excluding expenses incidental to the acquisition
which are written off to the Income statement).
Subsequently, the investments are valued at
‘fair value’, which is measured as follows:
• Investments listed on recognised
exchanges are valued at their bid prices at the end of the
accounting period or otherwise at fair value based on published
price quotations; • Unquoted investments, where there is not
an active market, are valued using an appropriate valuation
technique in accordance with the IPEV Guidelines. Indicators of
fair value are derived using established methodologies including
earnings multiples, the level of third party offers received, cost
or price of recent investment rounds, net assets and industry
valuation benchmarks. Where price of recent investment is used as a
starting point for estimating fair value at subsequent measurement
dates, this has been benchmarked using an appropriate valuation
technique permitted by the IPEV guidelines. • In situations
where cost or price of recent investment is used, consideration is
given to the circumstances of the portfolio company since that date
in determining fair value. This includes consideration of whether
there is any evidence of deterioration or strong definable evidence
of an increase in value. In the absence of these indicators, the
investment in question is valued at the amount reported at the
previous reporting date. Examples of events or changes that could
indicate a diminution include: o the performance and/or
prospects of the underlying business are significantly below the
expectations on which the investment was based; o a
significant adverse change either in the portfolio company’s
business or in the technological, market, economic, legal or
regulatory environment in which the business operates; or
o market conditions have deteriorated, which may be indicated
by a fall in the share prices of quoted businesses operating in the
same or related sectors.
Investments are recognised as financial assets
on legal completion of the investment contract and are
de-recognised on legal completion of the sale of an investment.
Dividend income is not recognised as part of the
fair value movement of an investment, but is recognised separately
as investment income through the Income statement when a share
becomes ex-dividend.
Current assets and payables
Receivables (including debtors due after more than one year),
payables and cash are carried at amortised cost, in accordance with
FRS 102. Deferred consideration meets the definition of a financing
transaction held at amortised cost, and interest will be recognised
through capital over the credit period using the effective interest
method. There are no financial liabilities other than payables.
Investment income Dividend
income Dividend income is included in revenue when the investment
is quoted ex-dividend.
Unquoted loan stock Fixed returns on non-equity
shares and debt securities are recognised when the Company’s right
to receive payment and expect settlement is established. Where
interest is rolled up and/or payable at redemption then it is
recognised as income unless there is reasonable doubt as to its
receipt.
Fixed term funds income Funds income is
recognised on an accruals basis using the agreed rate of
interest.
Bank deposit income Interest income is
recognised on an accruals basis using the rate of interest agreed
with the bank.
Investment management fee, performance
incentive fee and other expenses All expenses have been
accounted for on an accruals basis. Expenses are charged through
the other distributable reserve except the following which are
charged through the realised capital reserve:
- 90% of management fees and 100% performance incentive fees, if
any, are allocated to the realised capital reserve; and
- expenses which are incidental to the purchase or disposal of an
investment are charged through the realised capital reserve.
Taxation Taxation is applied on
a current basis in accordance with FRS 102. Current tax is tax
payable (refundable) in respect of the taxable profit (tax loss)
for the current period or past reporting periods using the tax
rates and laws that have been enacted or substantively enacted at
the financial reporting date. Taxation associated with capital
expenses is applied in accordance with the SORP.
Deferred tax is provided in full on all timing
differences at the reporting date. Timing differences are
differences between taxable profits and total comprehensive income
as stated in the financial statements that arise from the inclusion
of income and expenses in tax assessments in periods different from
those in which they are recognised in the financial statements. As
a VCT the Company has an exemption from tax on capital gains. The
Company intends to continue meeting the conditions required to
obtain approval as a VCT in the foreseeable future. The Company
therefore should have no material deferred tax timing differences
arising in respect of the revaluation or disposal of investments
and the Company has not provided for any deferred tax.
Share capital and reserves
Called-up share capital This reserve accounts for the nominal value
of the shares.
Share premium This reserve accounts for the
difference between the price paid for shares and the nominal value
of the shares, less issue costs and transfers to the other
distributable reserve.
Capital redemption reserve This reserve accounts
for amounts by which the issued share capital is diminished through
the repurchase and cancellation of the Company’s own shares.
Unrealised capital reserve Increases and
decreases in the valuation of investments held at the period end
against cost are included in this reserve.
Realised capital reserve The following are
disclosed in this reserve:
- gains and losses compared to cost on the realisation of
investments, or permanent diminutions in value (including gains
recognised on the realisation of investment where consideration is
deferred that are not distributable as a matter of law);
- finance income in respect of the unwinding of the discount on
deferred consideration that is not distributable as a matter of
law;
- expenses, together with the related taxation effect, charged in
accordance with the above policies; and
- dividends paid to equity holders where paid out by
capital.
Other distributable reserve The special reserve,
treasury share reserve and the revenue reserve were combined in
2012 to form a single reserve named other distributable
reserve.
This reserve accounts for movements from the
revenue column of the Income statement, the payment of dividends,
the buy-back of shares and other non-capital realised
movements.
Dividends Dividends by the
Company are accounted for in the period in which the dividend is
paid or approved at the Annual General Meeting.
Segmental reporting The
Directors are of the opinion that the Company is engaged in a
single operating segment of business, being investment in smaller
companies principally based in the UK.
3. (Losses)/gains
on investments
|
Unaudited six months ended 30 September
2023 £’000 |
Unaudited six months ended 30 September 2022 £’000 |
Audited
year ended 31 March 2023 £’000 |
Unrealised (losses)/gains on fixed asset investments |
(2,969) |
980 |
492 |
Realised
(losses)/gains on fixed asset investments |
(84) |
102 |
(176) |
Unwinding of
discount on deferred consideration |
147 |
125 |
261 |
|
(2,906) |
1,207 |
577 |
4. Investment
income
|
Unaudited six months
ended 30 September 2023
£’000 |
Unaudited six months ended 30 September 2022 £’000 |
Audited year ended 31 March 2023 £’000 |
Loan
stock interest |
441 |
482 |
941 |
Bank
interest |
158 |
12 |
55 |
Income
from fixed term funds |
96 |
22 |
85 |
Dividend
income |
74 |
91 |
121 |
|
769 |
607 |
1,202 |
5. Investment
management fee
|
Unaudited six months ended 30 September
2023 £’000 |
Unaudited six months ended 30 September 2022 £’000 |
Audited year ended 31 March 2023 £’000 |
Investment management fee charged to capital |
564 |
528 |
1,097 |
Investment management fee charged to revenue |
63 |
59 |
122 |
|
627 |
587 |
1,219 |
Further details of the Management agreement
under which the investment management fee and any performance
incentive fee is paid are given in the Strategic report on page 19
of the Annual Report and Financial Statements for the year ended 31
March 2023.
During the period, services of a total value of
£661,000 (30 September 2022: £617,000; 31 March 2023: £1,279,000),
were purchased by the Company from Albion Capital Group LLP; this
includes £627,000 (30 September 2022: £587,000; 31 March 2023:
£1,219,000) of investment management fee and £34,000 (30 September
2022: £30,000; 31 March 2023: £60,000) of secretarial and
administration fee. At the financial period end, the amount due to
Albion Capital Group LLP in respect of these services disclosed
within payables was £315,000 (30 September 2022: £301,000; 31 March
2023: £345,000).
Albion Capital Group LLP is, from time to time,
eligible to receive arrangement fees and monitoring fees from
portfolio companies. During the period to 30 September 2023, fees
of £51,000 attributable to the investments of the Company were
received pursuant to these arrangements (30 September 2022:
£104,000; 31 March 2023: £193,000).
Albion Capital Group LLP, its partners and staff
held a total of 1,487,317 shares in the Company on 30 September
2023.
6. Dividends
|
Unaudited six months ended
30 September 2023 £’000 |
Unaudited six months ended 30 September 2022 £’000 |
Audited year ended 31 March 2023 £’000 |
First
dividend of 1.27p per share paid on 31 July 2023 (29 July 2022:
First dividend of 1.33p per share) |
1,783 |
1,614 |
1,614 |
Second
dividend of 1.32p per share paid on 31 January 2023 |
- |
- |
1,716 |
Unclaimed
dividends |
- |
- |
(12) |
|
1,783 |
1,614 |
3,318 |
The Directors have declared a second dividend for the year ending
31 March 2024 of 1.19 pence per share (total approximately
£1,660,000), payable on 31 January 2024 to shareholders on the
register on 5 January 2024.
7. Basic and
diluted return/(loss) per share
|
Unaudited six months ended
30 September 2023 |
Unaudited six months ended 30 September 2022 |
Audited
year ended 31 March 2023 |
|
Revenue |
Capital |
Revenue |
Capital |
Revenue |
Capital |
Return/(loss) attributable to equity shares (£’000) |
368 |
(3,372) |
285 |
725 |
546 |
(421) |
Weighted
average shares in issue (adjusted for treasury shares) |
140,099,618 |
120,975,277 |
123,938,910 |
Return/(loss) attributable per equity share (pence) |
0.26 |
(2.41) |
0.24 |
0.60 |
0.44 |
(0.34) |
The weighted average number of shares is
calculated after adjusting for treasury shares of 20,615,500 (30
September 2022: 17,848,388; 31 March 2023: 19,137,781).
There are no convertible instruments,
derivatives or contingent share agreements in issue so basic and
diluted return per share are the same.
8. Called-up
share capital
Allotted, called-up and fully paid shares of 1 penny
each |
Unaudited 30 September 2023 |
Unaudited 30 September 2022 |
Audited 31 March 2023 |
Number of
shares |
160,072,698 |
138,135,653 |
158,716,332 |
Nominal
value of allotted shares (£’000) |
1,601 |
1,381 |
1,587 |
Voting rights (number of shares net of treasury shares) |
139,457,198 |
120,287,265 |
139,578,551 |
During the period to 30 September 2023 the
Company purchased 1,477,719 Ordinary shares (nominal value of
£14,777) to be held in treasury (30 September 2022: 914,702 shares
for cancellation and 694,957 to be held in treasury; 31 March 2023:
914,702 shares for cancellation and 1,984,350 to be held in
treasury) at a total cost of £698,000 (30 September 2022: £801,000;
31 March 2023: £1,440,000) representing 0.9% of the shares in issue
as at 30 September 2023.
The total number of Ordinary shares held in
treasury as at 30 September 2023 was 20,615,500 (30 September 2022:
17,848,388; 31 March 2023: 19,137,781) representing 12.9% of the
share capital as at 30 September 2023.
Under the terms of the Dividend Reinvestment
Scheme Circular dated 10 July 2008, the following new Ordinary
shares of nominal value 1 penny per share were allotted during the
period:
Date of allotment |
Number of shares allotted |
Aggregate nominal value of shares
(£’000) |
Issue price (pence per
share) |
Net invested (£’000) |
Opening-market price on allotment date
(pence per share) |
31 July
2023 |
548,397 |
5 |
49.61 |
271 |
47.20 |
|
|
|
|
|
|
The following new Ordinary shares of nominal value
1 penny each were allotted under the Albion VCTs Prospectus Top Up
Offers 2022/23 during the period:
Date of allotment |
Number of shares allotted |
Aggregate nominal value of shares (£’000) |
Issue price (pence per share) |
Net consideration received (£’000) |
Opening-market price on allotment date
(pence per share) |
14 April 2023 |
377,529 |
4 |
50.90 |
189 |
47.60 |
14 April
2023 |
48,922 |
- |
51.10 |
25 |
47.60 |
14 April
2023 |
381,518 |
4 |
51.40 |
191 |
47.60 |
|
807,969 |
|
|
405 |
|
9.
Commitments and
contingencies
As at 30 September 2023, the Company had no
financial commitments (30 September 2022 and 31 March 2023:
£nil).
There are no contingencies or guarantees of the
Company as at 30 September 2023 (30 September 2022 and 31 March
2023: £nil).
10. Post
balance sheet events
The following are the material post balance sheet
events since 30 September 2023:
- Disposal of Ophelos for proceeds of £0.9 million; and
- Investments totalling £1.8 million in 1 new and 4 existing
portfolio companies.
As announced on 30 October 2023, following a
formal tender process, Johnston Carmichael LLP were appointed as
the Company's Auditor.
11.
Related party
transactions
Other than transactions with the Manager as
described in note 5, there are no other related party
transactions.
12.
Going
concern
The Board has conducted a detailed assessment of
the Company’s ability to meet its liabilities as they fall due.
Cash flow forecasts are updated and discussed quarterly at Board
level and have been stress tested to allow for the forecasted
impact of the current economic climate and increasingly volatile
geopolitical backdrop. The Board has revisited and updated their
assessment of liquidity risk and concluded that it remains
unchanged since the last Annual Report and Financial Statements.
Further details can be found on page 87 of those accounts.
The portfolio of investments is diversified in
terms of sector and the major cash outflows of the Company (namely
investments, dividends and share buy-backs) are within the
Company’s control. Accordingly, after making diligent enquiries,
the Directors have a reasonable expectation that the Company has
adequate cash and liquid resources to continue in operational
existence for the foreseeable future. For this reason, the
Directors have adopted the going concern basis in preparing this
Half-yearly Financial Report and this is in accordance with the
Guidance on Risk Management, Internal Control and Related Financial
and Business Reporting issued by the Financial Reporting Council in
September 2014, and the subsequent updated Going concern, risk and
viability guidance issued by the FRC in 2021.
13. Other
information
The information set out in this Half-yearly
Financial Report does not constitute the Company’s statutory
accounts within the terms of section 434 of the Companies Act 2006
for the periods ended 30 September 2023 and 30 September 2022 and
is unaudited. The information for the year ended 31 March 2023 does
not constitute statutory accounts within the terms of section 434
of the Companies Act 2006 but is derived from the audited statutory
accounts for the financial year, which have been delivered to the
Registrar of Companies. BDO LLP, as Auditor of the 31 March 2023
accounts, reported on those accounts; their report was unqualified
and did not contain a statement under s498 (2) or (3) of the
Companies Act 2006.
14. Publication
This Half-yearly Financial Report is being sent
to shareholders and copies will be made available to the public at
the registered office of the Company, Companies House, the National
Storage Mechanism and also electronically at
www.albion.capital/funds/AAVC, where the Report can be accessed as
a PDF document in the ‘Financial Reports and Circulars’
section.
- Portfolio split by sector
Grafico Azioni Close Brothers Venture Cap (LSE:CVC)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Close Brothers Venture Cap (LSE:CVC)
Storico
Da Dic 2023 a Dic 2024